Nivalis Therapeutics (ALPN) Earns News Sentiment Rating of 0.09

News stories about Nivalis Therapeutics (NASDAQ:ALPN) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Nivalis Therapeutics earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.7135899255566 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Nivalis Therapeutics (NASDAQ:ALPN) traded down 0.49% during trading on Friday, reaching $8.06. The company’s stock had a trading volume of 34,351 shares. The company’s 50-day moving average is $9.14 and its 200-day moving average is $9.80. The company’s market capitalization is $10.80 million. Nivalis Therapeutics has a 1-year low of $7.50 and a 1-year high of $37.40.

ALPN has been the topic of a number of research reports. Zacks Investment Research lowered Nivalis Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Ladenburg Thalmann Financial Services initiated coverage on Nivalis Therapeutics in a report on Thursday, July 27th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, ValuEngine upgraded Nivalis Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $8.81.

TRADEMARK VIOLATION WARNING: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at

In other news, insider Value Fund L. P. Biotechnology purchased 17,806 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was bought at an average cost of $2.25 per share, for a total transaction of $40,063.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bvf Partners L. P/Il purchased 35,750 shares of the company’s stock in a transaction on Monday, June 5th. The shares were purchased at an average price of $2.29 per share, with a total value of $81,867.50. The disclosure for this purchase can be found here. Insiders have acquired 210,106 shares of company stock valued at $479,122 over the last 90 days. 3.00% of the stock is currently owned by insiders.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

What are top analysts saying about Nivalis Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nivalis Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit